Market research
AOR.LSE Rua Life Sciences Plc
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 20M
- P/E ratio
- Not available
- Analyst target
- 400
- Dividend yield
- 0.0%
- Beta
- 1.28
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB0033360586
- Market cap
- 20M
- P/E ratio
- Not available
- Analyst target
- 400
- Dividend yield
- 0.0%
- Beta
- 1.28
About
About Rua Life Sciences Plc
Rua Life Sciences Plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in the United Kingdom. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices, as well as Reaction Injection Molding technology for use in high-precision medical device components. It also develops bore polymer sealed grafts and soft tissue patches; and tri leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to Rua Life Sciences Plc in June 2020. Rua Life Sciences Plc was incorporated in 1996 and is based in Glasgow, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AOR.LSE discussion.
5 years, 6 months ago
Rua Life Sciences Plc is currently in a long term uptrend where the price is trading 39.4% above its 200 day moving average.
From a valuation standpoint, the stock is 90.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 41.3.
Based on the above factors, Rua Life Sciences Plc gets an overall score of 2/5.